Abnormal DNA methylation within genes of the steroidogenesis pathway two years after paediatric critical illness and association with stunted growth in height further in time.
Aldosterone
Children
Cortisol
Critical illness
DNA methylation
Growth
Height
Paediatrics
Sex steroids
Steroidogenesis
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
19 07 2023
19 07 2023
Historique:
received:
24
05
2023
accepted:
04
07
2023
medline:
21
7
2023
pubmed:
20
7
2023
entrez:
19
7
2023
Statut:
epublish
Résumé
Former critically ill children show an epigenetic age deceleration 2 years after paediatric intensive care unit (PICU) admission as compared with normally developing healthy children, with stunted growth in height 2 years further in time as physical correlate. This was particularly pronounced in children who were 6 years or older at the time of critical illness. As this age roughly corresponds to the onset of adrenarche and further pubertal development, a relation with altered activation of endocrine pathways is plausible. We hypothesised that children who have been admitted to the PICU, sex- and age-dependently show long-term abnormal DNA methylation within genes involved in steroid hormone synthesis or steroid sulphation/desulphation, possibly aggravated by in-PICU glucocorticoid treatment, which may contribute to stunted growth in height further in time after critical illness. In this preplanned secondary analysis of the multicentre PEPaNIC-RCT and its follow-up, we compared the methylation status of genes involved in the biosynthesis of steroid hormones (aldosterone, cortisol and sex hormones) and steroid sulphation/desulphation in buccal mucosa DNA (Infinium HumanMethylation EPIC BeadChip) from former PICU patients at 2-year follow-up (n = 818) and healthy children with comparable sex and age (n = 392). Adjusting for technical variation and baseline risk factors and corrected for multiple testing (false discovery rate < 0.05), former PICU patients showed abnormal DNA methylation of 23 CpG sites (within CYP11A1, POR, CYB5A, HSD17B1, HSD17B2, HSD17B3, HSD17B6, HSD17B10, HSD17B12, CYP19A1, CYP21A2, and CYP11B2) and 4 DNA regions (within HSD17B2, HSD17B8, and HSD17B10) that were mostly hypomethylated. These abnormalities were partially sex- (1 CpG site) or age-dependent (7 CpG sites) and affected by glucocorticoid treatment (3 CpG sites). Finally, multivariable linear models identified robust associations of abnormal methylation of steroidogenic genes with shorter height further in time, at 4-year follow-up. Children who have been critically ill show abnormal methylation within steroidogenic genes 2 years after PICU admission, which explained part of the stunted growth in height at 4-year follow-up. The abnormalities in DNA methylation may point to a long-term disturbance in the balance between active sex steroids and mineralocorticoids/glucocorticoids after paediatric critical illness, which requires further investigation.
Sections du résumé
BACKGROUND
Former critically ill children show an epigenetic age deceleration 2 years after paediatric intensive care unit (PICU) admission as compared with normally developing healthy children, with stunted growth in height 2 years further in time as physical correlate. This was particularly pronounced in children who were 6 years or older at the time of critical illness. As this age roughly corresponds to the onset of adrenarche and further pubertal development, a relation with altered activation of endocrine pathways is plausible. We hypothesised that children who have been admitted to the PICU, sex- and age-dependently show long-term abnormal DNA methylation within genes involved in steroid hormone synthesis or steroid sulphation/desulphation, possibly aggravated by in-PICU glucocorticoid treatment, which may contribute to stunted growth in height further in time after critical illness.
RESULTS
In this preplanned secondary analysis of the multicentre PEPaNIC-RCT and its follow-up, we compared the methylation status of genes involved in the biosynthesis of steroid hormones (aldosterone, cortisol and sex hormones) and steroid sulphation/desulphation in buccal mucosa DNA (Infinium HumanMethylation EPIC BeadChip) from former PICU patients at 2-year follow-up (n = 818) and healthy children with comparable sex and age (n = 392). Adjusting for technical variation and baseline risk factors and corrected for multiple testing (false discovery rate < 0.05), former PICU patients showed abnormal DNA methylation of 23 CpG sites (within CYP11A1, POR, CYB5A, HSD17B1, HSD17B2, HSD17B3, HSD17B6, HSD17B10, HSD17B12, CYP19A1, CYP21A2, and CYP11B2) and 4 DNA regions (within HSD17B2, HSD17B8, and HSD17B10) that were mostly hypomethylated. These abnormalities were partially sex- (1 CpG site) or age-dependent (7 CpG sites) and affected by glucocorticoid treatment (3 CpG sites). Finally, multivariable linear models identified robust associations of abnormal methylation of steroidogenic genes with shorter height further in time, at 4-year follow-up.
CONCLUSIONS
Children who have been critically ill show abnormal methylation within steroidogenic genes 2 years after PICU admission, which explained part of the stunted growth in height at 4-year follow-up. The abnormalities in DNA methylation may point to a long-term disturbance in the balance between active sex steroids and mineralocorticoids/glucocorticoids after paediatric critical illness, which requires further investigation.
Identifiants
pubmed: 37468957
doi: 10.1186/s13148-023-01530-9
pii: 10.1186/s13148-023-01530-9
pmc: PMC10354984
doi:
Substances chimiques
Glucocorticoids
0
DNA
9007-49-2
CYP21A2 protein, human
EC 1.14.14.16
Steroid 21-Hydroxylase
EC 1.14.14.16
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
116Informations de copyright
© 2023. The Author(s).
Références
Clin Cancer Res. 2019 Feb 15;25(4):1291-1301
pubmed: 30228209
Clin Endocrinol (Oxf). 2004 Mar;60(3):288-96
pubmed: 15008992
Gynecol Obstet Invest. 2013;76(4):209-13
pubmed: 24157654
J Ethnopharmacol. 2019 Jan 30;229:97-103
pubmed: 30195059
Trials. 2015 May 01;16:202
pubmed: 25927936
J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):141-4
pubmed: 9365183
Intensive Care Med. 2013 Sep;39(9):1584-93
pubmed: 23740280
Horm Res. 2008;70(5):257-67
pubmed: 18824863
Sex Dev. 2022;16(1):1-10
pubmed: 34649256
Endocr Rev. 2004 Dec;25(6):947-70
pubmed: 15583024
Curr Opin Crit Care. 2023 Apr 1;29(2):114-122
pubmed: 36794929
Methods Mol Biol. 2018;1708:303-330
pubmed: 29224151
Am J Kidney Dis. 2012 Apr;59(4):523-30
pubmed: 22206744
Biomed Pharmacother. 2013 Sep;67(7):651-7
pubmed: 23916544
J Clin Endocrinol Metab. 2014 Mar;99(3):E536-43
pubmed: 24423307
Clin Epigenetics. 2023 Jan 14;15(1):8
pubmed: 36639798
Lung Cancer. 2015 Feb;87(2):107-16
pubmed: 25564397
J Assist Reprod Genet. 2016 Aug;33(8):1105-13
pubmed: 27167072
Rev Endocr Metab Disord. 2009 Mar;10(1):3-17
pubmed: 18821018
Neurology. 2003 Dec 23;61(12):1779-82
pubmed: 14694046
Clin Endocrinol (Oxf). 2021 Nov;95(5):702-715
pubmed: 34368982
Lancet Child Adolesc Health. 2020 Jul;4(7):503-514
pubmed: 32562632
J Clin Endocrinol Metab. 1998 Mar;83(3):976-82
pubmed: 9506759
Epigenetics Chromatin. 2015 Jan 27;8:6
pubmed: 25972926
Horm Res Paediatr. 2012;78(4):261-8
pubmed: 22964562
Endocr Rev. 2011 Feb;32(1):81-151
pubmed: 21051590
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Bioinformatics. 2003 Feb 12;19(3):368-75
pubmed: 12584122
Lancet Respir Med. 2020 Mar;8(3):288-303
pubmed: 32085844
Minerva Endocrinol. 2010 Jun;35(2):109-25
pubmed: 20595939
J Clin Endocrinol Metab. 2020 Dec 1;105(12):
pubmed: 32844182
Rev Endocr Metab Disord. 2009 Mar;10(1):19-26
pubmed: 18821019
Epigenetics. 2023 Dec;18(1):2146966
pubmed: 36384393
J Steroid Biochem Mol Biol. 1992 Dec;43(8):895-906
pubmed: 22217834
J Steroid Biochem Mol Biol. 2014 Sep;143:451-9
pubmed: 25010478
Biomed Res Int. 2014;2014:460251
pubmed: 25210711
BMC Cancer. 2011 Dec 19;11:522
pubmed: 22176788
Neuropsychopharmacology. 2013 Jan;38(1):23-38
pubmed: 22781841
Endocr Rev. 2000 Dec;21(6):671-96
pubmed: 11133068
Endocr Rev. 2021 Nov 16;42(6):783-814
pubmed: 33788946
JAMA. 2012 Oct 24;308(16):1641-50
pubmed: 23101118
Environ Toxicol Pharmacol. 2011 Nov;32(3):356-63
pubmed: 22004954
Genome Biol. 2015 Feb 15;16:37
pubmed: 25853392
J Am Heart Assoc. 2018 May 8;7(10):
pubmed: 29739797
Endocr Rev. 2023 Jan 12;44(1):1-13
pubmed: 35639981
J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):212-8
pubmed: 18448329
J Endocrinol. 2014 May 12;221(2):347-62
pubmed: 24594617
Intensive Care Med. 2020 Jan;46(1):70-81
pubmed: 31713058
Clin Endocrinol (Oxf). 2020 Feb;92(2):98-108
pubmed: 31747461
Prostate. 2015 Nov;75(15):1790-801
pubmed: 26332453
Endocrinol Metab Clin North Am. 2015 Jun;44(2):243-74
pubmed: 26038200
Crit Care. 2022 May 12;26(1):133
pubmed: 35549984
Horm Res. 2005;64(4):157-65
pubmed: 16205094
JAMA Pediatr. 2022 Mar 01;176(3):e215767
pubmed: 35040918
Reprod Sci. 2022 May;29(5):1630-1643
pubmed: 34671938
Eur J Endocrinol. 2015 Aug;173(2):185-95
pubmed: 25953827
Sci Total Environ. 2021 Nov 25;797:149084
pubmed: 34303245
Bioinformatics. 2017 Feb 15;33(4):558-560
pubmed: 28035024
Cancer Cell. 2014 Oct 13;26(4):577-90
pubmed: 25263941
Nat Rev Genet. 2012 May 29;13(7):484-92
pubmed: 22641018
Brain Behav Immun. 2020 Jul;87:703-714
pubmed: 32156515
Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23329-23335
pubmed: 31611402
Lancet Respir Med. 2019 Feb;7(2):141-153
pubmed: 30224325
J Reprod Dev. 2005 Dec;51(6):715-25
pubmed: 16177546
N Engl J Med. 2016 Mar 24;374(12):1111-22
pubmed: 26975590
Endocr Rev. 2009 Dec;30(7):883-925
pubmed: 19887492